ModelOp Recognized in 2025 Gartner® Market Guide for AI Governance Platforms 
Market Value Lower Than Cash Assets? It’s Time to Reevaluate NIVF 
Winvest Group Announces Strategic Partnership with Greater Bay Area RWA Incubator; Southeast Asia Headquarters to Be Established in Malaysia Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma
80% overall survival rate at 24 months follow-up Oslo, 13 October 2021: Ultimovacs ASA (“Ultimovacs”)…
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations LONDON and RALEIGH, N.C., Oct. 13,…
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Data on Tedopi®, BiCKI® and CLEC-1 programs being presented in three poster presentations – November…
Nicox to present at the OIS Glaucoma Virtual Innovation Showcase
FOR INFORMATION Nicox to present at the OIS Glaucoma Virtual Innovation Showcase October 13, 2021…
Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
THR-687 is a potent pan-RGD integrin antagonist holding potential as a next generation first line…
Hyloris Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome
Potential to revolutionise the current treatment paradigm and become the cornerstone therapy for patients with…
Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after…
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is…
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage…
Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) − Enochian BioSciences, a company…
Travere Therapeutics Announces Transition of Chief Medical Officer
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH:…
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Study Approval Paves the Way for Trial Participants to Begin Taking Apabetalone CALGARY, Alberta, Oct….
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2021
Monthly information regarding the total number of voting rights and total number of shares of…
Neuronetics Announces Preliminary Revenue for Third Quarter 2021
MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical…
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA),…
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) — Adicet Bio, Inc. (Nasdaq:…
Evaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021
COPENHAGEN, Denmark, Oct. 12, 2021 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
Morphic to Participate in Jefferies IBD Therapeutics Summit
WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company…
Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU
– IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating…